3-MeO-PCPy

3-MeO-PCPy is not separately named in the federal schedules, but a substance meeting the statutory controlled-substance-analogue tests is treated as Schedule I to the extent it is intended for human consumption. Application depends on substantial chemical-structure similarity or substantially similar central-nervous-system effects and on the facts showing intended human consumption.

Argentina controls 3-MeO-PCPy through the arylcyclohexylamine chemical-group schedule in Annex II of Decree 560/2019 rather than by individual name. Its pyrrolidinyl amino ring and meta-methoxy phenyl substitution match the permitted 1-pyrrolidinyl amino-ring replacement and methoxy aromatic-ring substitution in Group 2. Article 2 treats substances within the Annex II chemical groups as estupefacientes for article 77 of the Penal Code.

At Commonwealth level, 3-MeO-PCPy is covered as a controlled-drug and border-controlled-drug analogue of listed phencyclidine. The compound is 3-methoxyrolicyclidine, which the analytical literature identifies as a phencyclidine derivative; section 301.9 covers chemical derivatives and also specifies heterocyclic-ring replacement and substitution between hydrogen and alkoxy groups. The Criminal Code Regulations list phencyclidine as both a controlled drug and a border controlled drug, so the analogue rules apply without 3-MeO-PCPy being named individually.

Austria’s NPS regulation covers every compound derivable from arylcyclohexylamine, arylcyclohexyl-pyrrolidine, or arylcyclohexyl-piperidine core structures. The NPS Act penalizes profit-motivated manufacture, import, export, transfer, or procurement carried out with the intent that the substance be used for psychoactive effect.

Canada’s Schedule I phencyclidine entry expressly includes its derivatives and analogues, while the Act defines an analogue by substantially similar chemical structure. 3-MeO-PCPy is a methoxy-substituted pyrrolidine analogue in the phencyclidine family and is covered through that entry rather than named separately.

The Shenzhen Public Security Bureau's official controlled-drug catalogue, updated on 17 July 2026 and expressly current through 1 July 2026, lists entry 229 as 1-[1-(3-甲氧基苯基)环己基]吡咯烷 / 1-(1-(3-Methoxyphenyl)cyclohexyl)pyrrolidine, CAS 1364933-79-8, abbreviation 3-MeO-PCPy. The three-agency 2025 consolidation announcement states that the Catalogue of Non-medical Narcotic Drugs and Psychotropic Substances took effect on publication and simultaneously repealed the former Supplementary Catalogue. The 17 June 2026 three-agency announcement added 16 substances effective 1 July 2026, while the later official police consolidation retains 3-MeO-PCPy at entry 229. Regulation Articles 3 and 4 establish the three-agency non-medical catalogue and permit non-medical controlled substances only for experimental research under the Regulation, prohibiting production, operation, use, storage, and transport. The scheduling measures also prohibit production, sale, transport, use, storage, and import or export, subject to regulated research and related exceptions. Public Security Administration Punishments Law Article 84 penalizes illegal possession of a small quantity of other drugs; Criminal Law Article 348 covers larger quantities, and Article 357 defines drugs to include other state-controlled addictive narcotic drugs and psychotropic substances. Accordingly, 3-MeO-PCPy is prohibited for ordinary possession and use, subject only to narrow authorized research-related activity.

Germany controls 3-MeO-PCPy through the arylcyclohexyl(methyl)amine group in Anlage 1 no. 6 of the NpSG rather than by individual name. Its pyrrolidinyl amine and methoxy-substituted phenyl ring fit the provision's permitted cyclic amine, phenyl R3, and alkoxy-substituent parameters, within the 500 u mass ceiling. Sections 2 and 3 classify substances in an Anlage 1 group as new psychoactive substances and prohibit trade, manufacture, import, export, transit, acquisition, possession, and administration, subject to statutory exceptions.

Ireland’s capacity-based definition covers substances that stimulate or depress the central nervous system and cause specified changes in perception, awareness, mood, or other functions. The Act criminalizes knowing or reckless sale for human consumption; it does not create a general personal-possession offence.

First Schedule item 11b lists PHP (PCPy/rolicyclidine), 1-(1-phenylcyclohexyl)pyrrolidine. The 2017 amendment extends item 11b to structural derivatives; 3-MeO-PCPy, 1-[1-(3-methoxyphenyl)cyclohexyl]pyrrolidine, adds a methoxy substituent to that parent scaffold and falls within the schedule's structural-derivative language. It is therefore controlled as a dangerous drug rather than named separately.

New Zealand's Misuse of Drugs Act 1975 automatically captures controlled-drug analogues as Class C controlled drugs when their chemical structure is substantially similar to that of a scheduled drug. PubChem identifies 3-MeO-PCPy as 1-[1-(3-methoxyphenyl)cyclohexyl]pyrrolidine and the scheduled PCPY parent as 1-(1-phenylcyclohexyl)pyrrolidine, so 3-MeO-PCPy differs from PCPY by a methoxy substituent on the phenyl ring and falls within the analogue rule. It is controlled as a Class C analogue rather than through an individual 3-MeO-PCPy schedule entry.

PubChem identifies 3-MeO-PCPy as 1-[1-(3-methoxyphenyl)cyclohexyl]pyrrolidine. Poland's NPS schedule covers arylcyclohexylamine derivatives up to 500 u and expressly permits an alkoxy substituent through C6 on the aryl ring and a pyrrolidinyl ring at nitrogen, placing this structure in group VII-NPS without an individual listing. Article 62b of the Act on Counteracting Drug Addiction penalizes unlawful possession of a new psychoactive substance, with imprisonment possible for a significant quantity. The 2025 and 2026 amending regulations do not alter group VII-NPS.

Russia controls 3-MeO-PCPy as a derivative of 1-phenylcyclohexylamine under List I of Government Decree No. 681 rather than by its individual name. Its structure is formed from the listed parent by formal substitution of aromatic hydrogen with methoxy and the two amine hydrogens with a divalent tetramethylene substituent, within the carbon-count rule in note 6. List I prohibits circulation of the listed narcotic drugs and their covered derivatives in the Russian Federation.

Singapore’s capacity-based framework applies to substances capable of producing a psychoactive effect even when they are not yet scheduled as controlled drugs. Part 2A criminalizes trafficking, manufacture, import, export, possession, and consumption, subject to the statutory exclusion schedule for legitimate-use substances.

Schedule 2 Part III lists phencyclidine and its named congeners, including PCPy, and extends the Part to homologues defined as chemically related substances with a similar structural fragment or similar pharmacodynamic properties. 3-MeO-PCPy is the 3-methoxy derivative of PCPy and falls within that broad homologue clause; unauthorized use, possession, and dealing are prohibited by sections 4 and 5.

South Korea’s Annex 3 places phencyclidine analogues in category “가” of psychotropic drugs. 3-MeO-PCPy is a methoxy-substituted pyrrolidine analogue in the phencyclidine family and is controlled through this generic analogue entry rather than by a separate short-name listing.

3-MeO-PCPy is covered by the generic arylcyclohexylamine entry in Schedule e rather than being individually named. The ordinance reaches phenylcyclohexylamine derivatives bearing a cyclic or heterocyclic nitrogen structure and an aromatic alkoxy substituent, matching 1-[1-(3-methoxyphenyl)cyclohexyl]pyrrolidine. Industrial and scientific use is excepted from control, but private use is expressly not excepted.

Ukraine's drug-control law treats analogues as substances prohibited from circulation when they are absent from the national list but have chemical structure and properties similar to controlled narcotic drugs or psychotropic substances and reproduce their psychoactive action. 3-MeO-PCPy is 3-methoxyrolicyclidine, and the analytical literature identifies it as a new psychoactive phencyclidine derivative, placing it within that analogue rule rather than an exact-name schedule entry. Its coverage therefore follows the statutory analogue test, not an inference that omission from the schedule makes it unscheduled.

The United Kingdom’s Class B generic definition covers compounds derived from 1-phenylcyclohexylamine by replacement of the amino group with a 1-pyrrolidyl group and by alkoxy substitution on the phenyl ring. The pyrrolidyl ring and 3-methoxy substituent of 3-MeO-PCPy place it within that structural definition.

Mexico requires prior COFEPRIS authorization to import or export covered medicines, drug chemicals, and raw materials that are or contain narcotics or psychotropics. Annex I(c) and (j) list rolicyclidine and its salts and derivatives under tariff heading 2933.99.99 for the import and export permit regimes; PubChem identifies 3-MeO-PCPy as 1-[1-(3-methoxyphenyl)cyclohexyl]pyrrolidine, the methoxy-substituted PCPy structure. The measure governs import and export and does not establish a general possession prohibition for 3-MeO-PCPy.